Clinical trial
Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced…
NCT00499525 · Northwestern University, Other · Unknown status
Key facts
| NCT number | NCT00499525 |
|---|---|
| Title | Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer |
| Official title | A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer |
| Lead sponsor | Northwestern University, Other |
| Collaborators | Amgen Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | paclitaxel, sorafenib tosylate, placebo |
| Enrollment | 180 |
| Start date | Jun 1, 2007 |
| Primary completion | Dec 1, 2020 |
| Completion | Dec 1, 2022 |
| First posted | Jul 11, 2007 |
| Last update posted | May 3, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: